9 results on '"Pavan Dhoble"'
Search Results
2. Low prevalence of primary sclerosing cholangitis in patients with inflammatory bowel disease in India
- Author
-
Arshdeep Singh, Vandana Midha, Vikram Narang, Saurabh Kedia, Ramit Mahajan, Pavan Dhoble, Bhavjeet Kaur Kahlon, Ashvin Singh Dhaliwal, Ashish Tripathi, Shivam Kalra, Narender Pal Jain, Namita Bansal, Rupa Banerjee, Devendra Desai, Usha Dutta, Vineet Ahuja, and Ajit Sood
- Subjects
colitis, ulcerative ,cholangitis, sclerosing ,prevalence ,inflammatory bowel diseases ,india ,Medicine ,Diseases of the digestive system. Gastroenterology ,RC799-869 - Abstract
Background/Aims Primary sclerosing cholangitis (PSC) represents the most common hepatobiliary extraintestinal manifestation of inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD). Limited data exist on PSC in patients with IBD from India. We aimed to assess the prevalence and disease spectrum of PSC in Indian patients with IBD. Methods Database of IBD patients at 5 tertiary care IBD centers in India were analyzed retrospectively. Data were extracted and the prevalence of PSC-IBD was calculated. Results Forty-eight patients out of 12,216 patients with IBD (9,231 UC, 2,939 CD, and 46 IBD unclassified) were identified to have PSC, resulting in a prevalence of 0.39%. The UC to CD ratio was 7:1. Male sex and pancolitis (UC) or colonic CD were more commonly associated with PSC-IBD. The diagnosis of IBD preceded the diagnosis of PSC in most of the patients. Majority of the patients were symptomatic for liver disease at diagnosis. Eight patients (16.66%) developed cirrhosis, 5 patients (10.41%), all UC, developed malignancies (3 colorectal cancer [6.25%] and 2 cholangiocarcinoma [4.16%]), and 3 patients died (2 decompensated liver disease [4.16%] and 1 cholangiocarcinoma [2.08%]) on follow-up. None of the patients mandated surgical therapy for IBD. Conclusions Concomitant PSC in patients with IBD is uncommon in India and is associated with lower rates of development of malignancies.
- Published
- 2023
- Full Text
- View/download PDF
3. Long‐term outcomes of anti‐tumor necrosis factor therapy and surgery in nonperianal fistulizing Crohn's disease
- Author
-
Sudheer K Vuyyuru, Devendra Desai, Saurabh Kedia, Pavan Dhoble, Pabitra Sahu, Bhaskar Kante, Samagra Agarwal, Sawan Bopanna, Rajan Dhingra, Pratap Mouli Venigalla, Raju Sharma, Siddhartha Datta Gupta, Govind Makharia, Peush Sahni, and Vineet Ahuja
- Subjects
anti‐tumor necrosis factor ,nonperianal fistula ,Diseases of the digestive system. Gastroenterology ,RC799-869 - Abstract
Abstract Background Unlike perianal fistula, long‐term outcomes of nonperianal fistulae (NPF) in Crohn's disease (CD) are not clear. We aimed to compare the outcomes of medical and surgical therapies in patients with NPF. Methods We retrospectively analyzed the records of patients of CD with NPF who were prospectively followed from January 2005 to December 2018. Results Of the 53 patients with NPF [mean age at presentation:29 ± 14 years; 54.7% male; median duration of follow‐up: 47 months (interquartile range [IQR]:26–76 months)], enteroenteric fistula (37.8%) was the most common presentation. Of 22 patients treated with anti‐tumor necrosis factor (TNF) therapy, complete response was achieved in 40.9% (n = 9). Overall probability of maintaining response was similar between the anti‐TNF and surgical groups (95.2% vs 82.4%; 71% vs 76%; and 63% vs 69%% [P = 0.8] at 1, 2, and 3 years, respectively), with only 13.6% of patients treated with biologicals requiring surgery over 56 months. Twenty‐one patients required upfront surgery (small bowel or ileocolonic resection with/without diversion; 28.5% emergent), with 47.6% postoperative recurrence over 36 months, of which nine patients required biologicals (77.7% response to anti‐TNF therapy). Long‐term outcome was comparable between medically and surgically treated patients; 6.4% developed tuberculosis on anti‐TNF therapy. Two patients (3.7%) developed malignancy (one ‐ enteroenteric, one ‐ colovesical). Conclusion Anti‐TNF therapy appears to be as effective as surgery in this retrospective analysis of patients with NPFCD, and it may be indicated in the absence of abscess and other complications. These patients are at higher risk of fistula‐associated malignancy, which requires a lower threshold for suspicion, especially over the long term in the presence of nonresponse to medical therapy.
- Published
- 2021
- Full Text
- View/download PDF
4. Self-reported Wheat Sensitivity in Irritable Bowel Syndrome and Healthy Subjects: Prevalence of Celiac Markers and Response to Wheat-free Diet
- Author
-
Pavan Dhoble, Anand Deshpande, Tarun Gupta, Shachish Doctor, Rajeshwari Basavanna, Devendra Desai, Philip Abraham, and Anand Joshi
- Subjects
medicine.medical_specialty ,Constipation ,Gluten sensitivity ,Non-celiac gluten sensitivity ,Human leukocyte antigen ,Food sensitivity ,Gastroenterology ,Serology ,Bloating ,Internal medicine ,medicine ,Irritable bowel syndrome ,chemistry.chemical_classification ,Transglutaminases ,business.industry ,HLA-DQ2 ,nutritional and metabolic diseases ,food and beverages ,medicine.disease ,Gluten ,Diarrhea ,chemistry ,HLA typing ,Original Article ,Neurology (clinical) ,medicine.symptom ,business - Abstract
Background/aims Most patients with irritable bowel syndrome (IBS) report food-related aggravation of symptoms. Wheat/gluten is one of the most commonly incriminated. We studied the prevalence of self-reported wheat sensitivity in patients with IBS and in a healthy population from a region in India consuming mixed-cereal diets, correlated it with serological and human leukocyte antigen (HLA) markers of celiac disease, and evaluated the response to a wheat-free diet. Methods We surveyed 204 patients with IBS and 400 healthy persons for self-reported wheat sensitivity. Testing for IgA anti-tissue transglutaminase and HLA DQ2 or DQ8 was done in individuals who reported wheat sensitivity. Consenting persons with wheat sensitivity were put on wheat-free diet and monitored for symptom change. Results Twenty-three of 204 patients with IBS (11.3%) and none of the healthy subjects self-reported wheat sensitivity. Of 23 patients, 14 (60.9%) were positive for HLA DQ2 or DQ8 and none for anti-tissue transglutaminase antibody. After 6 weeks on wheat-free diet, all 19 participating patients reported clinical improvement; fewer patients had bloating, diarrhea, constipation, and easy fatigue. Conclusions Eleven percent of patients with IBS self-reported wheat sensitivity. None of them had positive celiac serology; 60.9% were positive for HLA DQ2 and DQ8, suggesting a possible genetic basis. All of them improved symptomatically on a wheat-free diet.
- Published
- 2021
- Full Text
- View/download PDF
5. Low prevalence of primary sclerosing cholangitis in patients with inflammatory bowel disease in India
- Author
-
Arshdeep Singh, Vandana Midha, Vikram Narang, Saurabh Kedia, Ramit Mahajan, Pavan Dhoble, Bhavjeet Kaur Kahlon, Ashvin Singh Dhaliwal, Ashish Tripathi, Shivam Kalra, Narender Pal Jain, Namita Bansal, Rupa Banerjee, Devendra Desai, Usha Dutta, Vineet Ahuja, and Ajit Sood
- Subjects
Gastroenterology - Abstract
Primary sclerosing cholangitis (PSC) represents the most common hepatobiliary extraintestinal manifestation of inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD). Limited data exist on PSC in patients with IBD from India. We aimed to assess the prevalence and disease spectrum of PSC in Indian patients with IBD.Database of IBD patients at 5 tertiary care IBD centers in India were analyzed retrospectively. Data were extracted and the prevalence of PSC-IBD was calculated.Forty-eight patients out of 12,216 patients with IBD (9,231 UC, 2,939 CD, and 46 IBD unclassified) were identified to have PSC, resulting in a prevalence of 0.39%. The UC to CD ratio was 7:1. Male sex and pancolitis (UC) or colonic CD were more commonly associated with PSC-IBD. The diagnosis of IBD preceded the diagnosis of PSC in most of the patients. Majority of the patients were symptomatic for liver disease at diagnosis. Eight patients (16.66%) developed cirrhosis, 5 patients (10.41%), all UC, developed malignancies (3 colorectal cancer [6.25%] and 2 cholangiocarcinoma [4.16%]), and 3 patients died (2 decompensated liver disease [4.16%] and 1 cholangiocarcinoma [2.08%]) on follow-up. None of the patients mandated surgical therapy for IBD.Concomitant PSC in patients with IBD is uncommon in India and is associated with lower rates of development of malignancies.
- Published
- 2022
6. Is the rise in Crohn's disease in India accompanied by a fall in intestinal tuberculosis? A single-center experience
- Author
-
Pavan Dhoble, Philip Abraham, and Devendra Desai
- Subjects
Adult ,Male ,medicine.medical_specialty ,Tuberculosis ,Colon ,India ,Single Center ,Inflammatory bowel disease ,Medical Records ,Crohn Disease ,Ileum ,Internal medicine ,Epidemiology ,medicine ,Humans ,Retrospective Studies ,Crohn's disease ,GeneXpert MTB/RIF ,business.industry ,Medical record ,Incidence (epidemiology) ,Incidence ,medicine.disease ,Infectious Diseases ,Tuberculosis, Gastrointestinal ,Female ,business - Abstract
The relationship between the incidence of intestinal tuberculosis (TB) and Crohn's disease (CD) is interesting, especially considering the striking similarity between the two conditions. Some studies from Asian populations suggested that the incidence of intestinal TB decreases when there is an increase in CD.To compare the incidence trend between intestinal TB and CD over 15 years.Medical records of patients seen in the Division of Gastroenterology over 15 years (2005-2019) were reviewed. CD was diagnosed according to the Copenhagen criteria. Intestinal TB was diagnosed in the appropriate clinical situation if any one or more of the following was present: (1) positive TB MGIT culture; (2) positive Gene Xpert for TB; (3) suggestive histologic findings, with positive tissue acid-fast bacillus (AFB) on smear or with sustained response to anti-TB therapy. The incidence time trend of patients with CD and intestinal TB diagnosis was then studied year-wise.632 medical case records were accessed; 60 patients were excluded due to inadequate data or not fulfilling diagnostic criteria. The 572 patients included 224 with intestinal TB (median age 37 years, IQR 22; 125 [56%] females) and 348 with CD (median age 40 years, IQR 25; 159 [46%] females [p 0.02 as compared to TB]). Thus, more patients with CD were seen during the study period, but there was no correlation between the incidence of the two conditions (r = 0.318; p = 0.25).In Indian patients in a single private-sector center, there was no inverse correlation between the incidence of intestinal TB and CD over 15 years.
- Published
- 2020
7. Progression of Chronic Liver Disease and Determinants of Outcome: Acute Decompensation Versus Acute-On-Chronic Liver Failure
- Author
-
Suman Talukdar, Philip Abraham, Devendra Desai, Tarun Gupta, and Pavan Dhoble
- Subjects
Hepatology - Published
- 2022
- Full Text
- View/download PDF
8. Ileocecal Resection in Crohn's Disease: REMIND Group Study
- Author
-
Ajinkya Sonambekar, Pavan Dhoble, Joshi Harshad, Devendra Desai, and Philip Abraham
- Subjects
0301 basic medicine ,medicine.medical_specialty ,medicine.medical_treatment ,MEDLINE ,Anastomosis ,Gastroenterology ,03 medical and health sciences ,0302 clinical medicine ,Postoperative Complications ,Crohn Disease ,Internal medicine ,medicine ,Humans ,Prospective Studies ,Prospective cohort study ,Colectomy ,Crohn's disease ,Hepatology ,Group study ,Crohn disease ,business.industry ,General surgery ,Anastomosis, Surgical ,Ileocecal resection ,medicine.disease ,030104 developmental biology ,030211 gastroenterology & hepatology ,business - Published
- 2017
9. Adalimumab in Crohn's strictures--the CREOLE study
- Author
-
Anand Joshi, Devendra Desai, Pavan Dhoble, and Ajinkya Sonambekar
- Subjects
medicine.medical_specialty ,business.industry ,Creole language ,Gastroenterology ,Adalimumab ,Anti-Inflammatory Agents ,Disease ,Constriction, Pathologic ,medicine.disease ,Inflammatory bowel disease ,Surgery ,03 medical and health sciences ,0302 clinical medicine ,Treatment Outcome ,Crohn Disease ,030220 oncology & carcinogenesis ,Internal medicine ,medicine ,Humans ,030211 gastroenterology & hepatology ,In patient ,business ,Intestinal Obstruction ,medicine.drug - Abstract
We compliment the authors of the CREOLE study1 evaluating the efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture. That about two-thirds of patients responded at 24 weeks and about a third of the symptomatic patients were able to avoid surgery at 4 years is impressive. The authors also need …
- Published
- 2017
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.